Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials.
Rik J VerheijdenJolien S de GrootBabs O FabriekMiki N HewKatie M O'BrienKarlijn P M SuijkerbuijkPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Higher corticosteroid peak dose for trAEs is associated with worse survival across tumor types, while cumulative dose is not. Too few patients received second-line immunosuppressants to confirm or reject an association with survival. These data argue for a reconsideration of irAE management approaches, starting with lower corticosteroid dose whenever feasible.
Keyphrases
- clinical trial
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- dna damage
- prognostic factors
- peritoneal dialysis
- free survival
- randomized controlled trial
- cell cycle
- electronic health record
- machine learning
- cell proliferation
- study protocol
- deep learning
- data analysis
- patient reported